Glaxo’s Witty Has Bigger Problem Than China as Sales Drop
This article is for subscribers only.
Andrew Witty, chief executive officer of GlaxoSmithKline Plc, has a challenge overseas. It’s just not the one that’s been making headlines.
While the media has been obsessed with the corruption investigation that has enveloped Glaxo in China, investors are more worried about the U.K. drugmaker’s disappointing performance, and particularly sales of its hallmark respiratory medicines in the U.S.